Congenital chylothorax (CC) can result from a congenital malformation or an acquired obstruction or disruption of the thoracic duct. Recently, oral administration of the phosphodiesterase-5 inhibitor, sildenafil, was reported to be effective in resolving non-pulmonary lymphatic malformations in infants and young children. We report a case of CC in a late preterm infant with congenital pulmonary lymphangiectasia where octreotide was not effective, but management with oral sildenafil was successful.

AbstractsThere was no significant mortality difference between SpO 2 targets overall. There was significant heterogeneity between old and new software on mortality (test for interaction p=0.006).* Using new software, targeting 91-95% increased hospital survival by 7.4% (from 76.8% to 84.2%) versus targeting 85-89% (p=0.0015).** Conclusions Pending the primary outcome of disability free survival at 2 years it appears wise not to target 85-89%. References Background Hypoxic-ischemic encephalopathy due to perinatal hypoxia-induced free radical formation is an important cause of long-term neurodevelopmental disabilities. Allopurinol reduces the formation of free radicals, which potentially limits hypoxia-induced reperfusion damage. With this trial we aimed to assess whether maternal allopurinol treatment during fetal hypoxia would reduce the release of brain-tissue-specific biomarkers associated with neonatal brain damage. Methods We performed a randomized double blind placebo controlled multicenter trial (NCT00189007) studying laboring women at term with imminent fetal hypoxia. Fetal distress was suspected in case of an abnormal fetal heart rate trace, ST-wave abnormalities on fetal ECG or fetal scalp pH<7.20. Women were allocated to